Skip to content

Study on the timing of testing heart artery function in patients with heart complaints (EDIT-CFT)

Routine versus selective coronary vasomotor function testing in ANOCA: a randomised controlled clinical trial - Study on the timing of testing heart artery function in patients with heart complaints (EDIT-CFT)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON58586
Enrollment
170
Registered
2025-09-10
Start date
2026-06-15
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina with non-obstructive coronary arteries (ANOCA), non-obstructive coronary artery disease (NOCAD), ischemia with non-obstructive coronary arteries (INOCA). Coronary vasomotor dysfunction (CVDys)

Interventions

170 ANOCA patients will be 1:1 randomised to either routine CFT or selective CFT. In the routine CFT arm, patients will be scheduled for CFT within four weeks after inclusion, and treatment will be ta
In the case of invalidating and/or intolerable symptoms, the treating cardiologist may decide to perform CFT earlier than six months after presentation.&nbsp

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: At least 18 years of ageAnginal pain and non-obstructive coronary arteries on coronary CT scanAble to complete Dutch questionnairesWritten informed consent

Exclusion criteria

Exclusion criteria: Limited life expectancy (Active desire for) pregnancyOther cause of angina than CVDys highly likelyCertain cardiac history (myocardial infarction, CABG, PCI, heart failure, valvular heart disease), severe renal dysfunctionContra-indication to CFT

Design outcomes

Primary

MeasureTime frame
The primary outcome is angina-related quality of life at 6-month follow-up quantified by the within-subject change in the Seattle Angina Questionnaire summary score (SAQSS). 

Secondary

MeasureTime frame
Secondary endpoints include anginal complaints at 6-month follow-up, quality of life at 3- and 6-month follow-up, and the proportion of patients whose symptoms have resolved and whose anti-anginal medication has been discontinued at 3- and 6-month follow-up. 

Countries

Netherlands

Contacts

Public ContactF.W. Adriaansen

Radboud Universitair Medisch Centrum

onderzoek.cardio@radboudumc.nl0243616785

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026